STAT3 can be activated through paracrine signaling in breast epithelial cells
Creators
- 1. Ohio State Biochemistry Program, The Ohio State University, Columbus (United States)
- 2. Department of Pediatrics, The Ohio State University, Columbus (United States)
- 3. Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus (United States)
- 4. Human Cancer Genetics Program, The Ohio State University, Columbus (United States)
- 5. Division of Medical Technology, School of Allied Medical Professions, The Ohio State University, Columbus (United States)
- 6. Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus (United States)
- 7. The Research Institute at Nationwide Children's Hospital, The Ohio State University, WA5020 Research Building II, 700 Children's Drive, Columbus, OH 43205 (United States)
- 8. Experimental Therapeutics Program, The Ohio State University Comprehensive Cancer Center, The Ohio State University, Columbus (United States)
Description
Many cancers, including breast cancer, have been identified with increased levels of phosphorylated or the active form of Signal Transducers and Activators of Transcription 3 (STAT3) protein. However, whether the tumor microenvironment plays a role in this activation is still poorly understood. Conditioned media, which contains soluble factors from MDA-MB-231 and MDA-MB-468 breast cancer cells and breast cancer associated fibroblasts, was added to MCF-10A breast epithelial and MDA-MB-453 breast cancer cells. The stimulation of phosphorylated STAT3 (p-STAT3) levels by conditioned media was assayed by Western blot in the presence or absence of neutralized IL-6 antibody, or a JAK/STAT3 inhibitor, JSI-124. The stimulation of cell proliferation in MCF-10A cells by conditioned media in the presence or absence of JSI-124 was subjected to MTT analysis. IL-6, IL-10, and VEGF levels were determined by ELISA analysis. Our results demonstrated that conditioned media from cell lines with constitutively active STAT3 are sufficient to induce p-STAT3 levels in various recipients that do not possess elevated p-STAT3 levels. This signaling occurs through the JAK/STAT3 pathway, leading to STAT3 phosphorylation as early as 30 minutes and is persistent for at least 24 hours. ELISA analysis confirmed a correlation between elevated levels of IL-6 production and p-STAT3. Neutralization of the IL-6 ligand or gp130 was sufficient to block increased levels of p-STAT3 (Y705) in treated cells. Furthermore, soluble factors within the MDA-MB-231 conditioned media were also sufficient to stimulate an increase in IL-6 production from MCF-10A cells. These results demonstrate STAT3 phosphorylation in breast epithelial cells can be stimulated by paracrine signaling through soluble factors from both breast cancer cells and breast cancer associated fibroblasts with elevated STAT3 phosphorylation. The induction of STAT3 phosphorylation is through the IL-6/JAK pathway and appears to be associated with cell proliferation. Understanding how IL-6 and other soluble factors may lead to STAT3 activation via the tumor microenvironment will provide new therapeutic regimens for breast carcinomas and other cancers with elevated p-STAT3 levels
Availability note (English)
Available from http://dx.doi.org/10.1186/1471-2407-8-302; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2582243Additional details
Identifiers
Publishing Information
- Journal Title
- BMC Cancer (Online)
- Journal Volume
- 8
- Journal Page Range
- p. 302
- ISSN
- 1471-2407
INIS
- Country of Publication
- United Kingdom
- Country of Input or Organization
- International Atomic Energy Agency (IAEA)
- INIS RN
- 46092070
- Subject category
- S62: RADIOLOGY AND NUCLEAR MEDICINE;
- Descriptors DEI
- ANTIBODIES; CARCINOMAS; CELL PROLIFERATION; CORRELATIONS; ENZYME IMMUNOASSAY; FIBROBLASTS; MAMMARY GLANDS; PHOSPHORYLATION; PROTEINS; SIGNALS; STIMULATION; TRANSCRIPTION
- Descriptors DEC
- ANIMAL CELLS; BIOASSAY; BODY; CHEMICAL REACTIONS; CONNECTIVE TISSUE CELLS; DISEASES; GLANDS; IMMUNOASSAY; NEOPLASMS; ORGANIC COMPOUNDS; ORGANS; SOMATIC CELLS
Optional Information
- Copyright
- Copyright (c) 2008 Lieblein et al
- Notes
- PMCID: PMC2582243; PUBLISHER-ID: 1471-2407-8-302; PMID: 18939993; OAI: oai:pubmedcentral.nih.gov:2582243; licensee BioMed Central Ltd.